Advertisement

Topics

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

07:17 EST 8 Nov 2017 | Labiotech.eu

InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal ...

This awesome article German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

NEXT ARTICLE

More From BioPortfolio on "German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...